Last reviewed · How we verify
A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
A multi-center, randomized, controlled clinical trial to evaluate the short-term and long-term efficacy and safety of mycophenolate mofetil (MMF) in reducing proteinuria and preserving renal function in patients with IgAN who have pre-treated (and continue to be treated) with angiotensin II receptor blockers (ARB), compared to the corticosteroids.
Details
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 151 |
| Start date | 2007-09 |
| Completion | 2019-05 |
Conditions
- IgA Nephropathy
Interventions
- irbesartan
- methylprednisolone (MP) or prednisone (pred)
- mycophenolate mofetil (MMF)
Primary outcomes
- Remission of proteinuria (complete or partial) — up to 4.3 years
Countries
China